A Randomized Placebo-controlled Phase II Trial of Irradiated, Adenovirus Vector Transferred GM-CSF Secreting Autologous Leukemia Cell Vaccination (GVAX) Versus Placebo Vaccination in Patients With Advanced MDS/AML After Allogeneic Hematopoietic Stem Cell Transplantation
Phase of Trial: Phase II
Latest Information Update: 05 Jul 2018
At a glance
- Drugs Tumour cell vaccine-GVAX (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- 26 Jan 2016 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov record.
- 29 Jan 2015 Planned End Date changed from 1 Jul 2016 to 1 Jan 2033 as reported by ClinicalTrials.gov record.
- 30 Jan 2013 New trial record